Global and Japan Castration Resistant Prostate Cancer Treatment Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Hormonal Therapy
  • 1.2.3 Adding An Anti-Androgen
  • 1.2.4 Stopping An Anti-Androgen
  • 1.2.5 Estrogens
  • 1.2.6 Chemotherapy
  • 1.2.7 Radiation Therapy
  • 1.2.8 Others
• 1.3 Market by Application
  • 1.3.1 Global Castration Resistant Prostate Cancer Treatment Market Share by Application: 2020 VS 2026
  • 1.3.2 Hospital
  • 1.3.3 Ambulatory Surgical Centers
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Castration Resistant Prostate Cancer Treatment Market Perspective (2015-2026)
• 2.2 Global Castration Resistant Prostate Cancer Treatment Growth Trends by Regions
  • 2.2.1 Castration Resistant Prostate Cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Castration Resistant Prostate Cancer Treatment Historic Market Share by Regions (2015-2020)
  • 2.2.3 Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Castration Resistant Prostate Cancer Treatment Players by Market Size
  • 3.1.1 Global Top Castration Resistant Prostate Cancer Treatment Players by Revenue (2015-2020)
  • 3.1.2 Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Players (2015-2020)
• 3.2 Global Castration Resistant Prostate Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Castration Resistant Prostate Cancer Treatment Revenue
• 3.4 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio
  • 3.4.1 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Castration Resistant Prostate Cancer Treatment Revenue in 2019
• 3.5 Key Players Castration Resistant Prostate Cancer Treatment Area Served
• 3.6 Key Players Castration Resistant Prostate Cancer Treatment Product Solution and Service
• 3.7 Date of Enter into Castration Resistant Prostate Cancer Treatment Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Castration Resistant Prostate Cancer Treatment Breakdown Data by Type (2015-2026)

• 4.1 Global Castration Resistant Prostate Cancer Treatment Historic Market Size by Type (2015-2020)
• 4.2 Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Type (2021-2026)

5 Castration Resistant Prostate Cancer Treatment Breakdown Data by Application (2015-2026)

• 5.1 Global Castration Resistant Prostate Cancer Treatment Historic Market Size by Application (2015-2020)
• 5.2 Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
• 6.2 North America Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
• 6.3 North America Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
• 6.4 North America Castration Resistant Prostate Cancer Treatment Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
• 7.2 Europe Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
• 7.3 Europe Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
• 7.4 Europe Castration Resistant Prostate Cancer Treatment Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
• 8.2 China Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
• 8.3 China Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
• 8.4 China Castration Resistant Prostate Cancer Treatment Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
• 9.2 Japan Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
• 9.3 Japan Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
• 9.4 Japan Castration Resistant Prostate Cancer Treatment Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
• 10.2 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
• 10.3 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
• 10.4 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 Active Biotech
  • 11.1.1 Active Biotech Company Details
  • 11.1.2 Active Biotech Business Overview
  • 11.1.3 Active Biotech Castration Resistant Prostate Cancer Treatment Introduction
  • 11.1.4 Active Biotech Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020))
  • 11.1.5 Active Biotech Recent Development
• 11.2 Diagnocure
  • 11.2.1 Diagnocure Company Details
  • 11.2.2 Diagnocure Business Overview
  • 11.2.3 Diagnocure Castration Resistant Prostate Cancer Treatment Introduction
  • 11.2.4 Diagnocure Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
  • 11.2.5 Diagnocure Recent Development
• 11.3 Glaxosmithkline
  • 11.3.1 Glaxosmithkline Company Details
  • 11.3.2 Glaxosmithkline Business Overview
  • 11.3.3 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Introduction
  • 11.3.4 Glaxosmithkline Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
  • 11.3.5 Glaxosmithkline Recent Development
• 11.4 Northwest Biotherapeutics
  • 11.4.1 Northwest Biotherapeutics Company Details
  • 11.4.2 Northwest Biotherapeutics Business Overview
  • 11.4.3 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Introduction
  • 11.4.4 Northwest Biotherapeutics Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
  • 11.4.5 Northwest Biotherapeutics Recent Development
• 11.5 Millennium Pharmaceuticals
  • 11.5.1 Millennium Pharmaceuticals Company Details
  • 11.5.2 Millennium Pharmaceuticals Business Overview
  • 11.5.3 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
  • 11.5.4 Millennium Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
  • 11.5.5 Millennium Pharmaceuticals Recent Development
• 11.6 Hologic
  • 11.6.1 Hologic Company Details
  • 11.6.2 Hologic Business Overview
  • 11.6.3 Hologic Castration Resistant Prostate Cancer Treatment Introduction
  • 11.6.4 Hologic Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
  • 11.6.5 Hologic Recent Development
• 11.7 Spectrum Pharmaceuticals
  • 11.7.1 Spectrum Pharmaceuticals Company Details
  • 11.7.2 Spectrum Pharmaceuticals Business Overview
  • 11.7.3 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
  • 11.7.4 Spectrum Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
  • 11.7.5 Spectrum Pharmaceuticals Recent Development
• 11.8 Abbott Laboratories
  • 11.8.1 Abbott Laboratories Company Details
  • 11.8.2 Abbott Laboratories Business Overview
  • 11.8.3 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Introduction
  • 11.8.4 Abbott Laboratories Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
  • 11.8.5 Abbott Laboratories Recent Development
• 11.9 Bayer Healthcare Pharmaceuticals
  • 11.9.1 Bayer Healthcare Pharmaceuticals Company Details
  • 11.9.2 Bayer Healthcare Pharmaceuticals Business Overview
  • 11.9.3 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
  • 11.9.4 Bayer Healthcare Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
  • 11.9.5 Bayer Healthcare Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer